XML 19 R4.htm IDEA: XBRL DOCUMENT v3.3.1.900
Consolidated Statements of Operations - USD ($)
 3 Months Ended 12 Months Ended
Dec. 31, 2015
Sep. 30, 2015
Jun. 30, 2015
Mar. 31, 2015
Dec. 31, 2014
Sep. 30, 2014
Jun. 30, 2014
Mar. 31, 2014
Dec. 31, 2015
Dec. 31, 2014
Dec. 31, 2013
Revenues:                      
Revenue under collaborative research and development arrangements $ 1,820,643 $ 16,475,083 $ 4,335,236 $ 4,245,571 $ 1,758,108 $ 1,114,952 $ 3,107,781 $ 1,435,727 $ 26,876,533 $ 7,416,568 $ 9,239,547
Revenue under collaborative research and development arrangements with affiliated entity 375,000 125,000 166,667 112,500 112,500 112,500 137,500 116,964 779,167 479,464 425,000
Grants and miscellaneous revenue 3,739,919 7,583,151 784,775 808,566 586,500 612,901 556,381 804,952 12,916,411 2,560,734 3,802,799
Total revenues 5,935,562 24,183,234 5,286,678 5,166,637 2,457,108 1,840,353 3,801,662 2,357,643 40,572,111 10,456,766 13,467,346
Operating expenses:                      
Research and development 15,601,891 16,075,201 16,688,511 9,426,320 9,244,473 7,017,805 9,607,281 8,225,480 57,791,923 34,095,039 21,368,604
General and administrative 4,860,086 4,377,616 4,718,260 4,107,928 4,224,429 3,153,714 4,347,327 4,132,218 18,063,890 15,857,688 13,643,074
Gain on sale of assets 0 0 (1,000,000) 0         (1,000,000) 0 (2,000,000)
Total operating expenses 20,461,977 20,452,817 20,406,771 13,534,248 13,468,902 10,171,519 13,954,608 12,357,698 74,855,813 49,952,727 33,011,678
Loss from operations (14,526,415) 3,730,417 (15,120,093) (8,367,611) (11,011,794) (8,331,166) (10,152,946) (10,000,055) (34,283,702) (39,495,961) (19,544,332)
Other income (expense):                      
Interest and other income, net (194,519) 214,982 146,332 138,276 113,212 97,174 68,999 52,076 305,071 331,461 132,214
Change in fair value of common stock warrants (290,316) 518,877 (49,773) (1,227) 143,659 (113,980) 824,390 (505,926) 177,561 348,143 (45,632,669)
Gain (Loss) on investment in affiliated entity (3,249,315) (659,054) 8,861,145 (2,352,309) 3,342,436 1,168,911 (1,458,160) (376,963) 2,600,467 2,676,224 (1,038,745)
Net loss before income tax benefit (18,260,565) 3,805,222 (6,162,389) (10,582,871)         (31,200,603) (36,140,133) (66,083,532)
Income tax benefit 308,520 1,789,246 0 0         2,097,766 0 0
Net loss (17,952,045) 5,594,468 (6,162,389) (10,582,871) (7,412,487) (7,179,061) (10,717,717) (10,830,868) (29,102,837) (36,140,133) (66,083,532)
Net (income) loss attributable to non-controlling interest 0 0 (85,861) 1,092 1,083 1,486 6,443 9,408 (84,769) 18,420 55,084
Net loss attributable to Inovio Pharmaceuticals, Inc. $ (17,952,045) $ 5,594,468 $ (6,248,250) $ (10,581,779) $ (7,411,404) $ (7,177,575) $ (10,711,274) $ (10,821,460) $ (29,187,606) $ (36,121,713) $ (66,028,448)
Net loss per common share attributable to Inovio Pharmaceuticals, Inc. stockholders                      
Basic ($ per share) $ (0.25) $ 0.08 $ (0.09) $ (0.17) $ (0.12) $ (0.12) $ (0.18) $ (0.20) $ (0.43) $ (0.61) $ (1.43)
Diluted ($ per share) $ (0.25) $ 0.07 $ (0.09) $ (0.18) $ (0.12) $ (0.12) $ (0.19) $ (0.20) $ (0.44) $ (0.64) $ (1.43)
Weighted average number of common shares outstanding used in per share calculations:                      
Basic (in shares) 72,194,504 72,029,644 67,655,975 60,741,082 60,610,367 60,392,911 60,232,498 55,159,002 68,198,142 59,127,349 46,087,773
Diluted (in shares) 72,194,504 73,961,237 67,838,738 60,913,423 60,805,871 60,602,831 60,474,859 55,159,002 68,365,265 59,408,252 46,087,773